Fig. 1From: Omalizumab therapy in a 13-year-old boy with severe persistent asthma and concomitant eosinophilic esophagitisFEV1 (% predictive value) longitudinal profile in our patient. Changes in forced respiratory volume in 1 s (FEV1) over time are shown for different treatments. FEV1 significantly improved during omalizumab therapy. The most representative detections are representedBack to article page